^
Association details:
| Biomarker: | PRR13/THBS1 ratio elevation |
|---|---|
| Cancer: | Ovarian Cancer |
| Regimen: | CaT (carboplatin + paclitaxel) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy
Excerpt:
Microdissected formalin-fixed tumoral samples from 187 EOC patients’ primary tumors (90 and 97 samples from matched patients in the experimental and validation sets, respectively) were analyzed....Most of the patients (172 out of 187) received front-line carboplatin-paclitaxel regimen....Multivariate analysis demonstrated that high PRR13/low THBS1 expression was an independent factor for decreased PFS (hazards ratio: 1.94; 95% confidence interval (CI): 1.48–2.92; P=0.008) and OS (hazard ratio: 3.89; 95% CI: 2.16–6.87; P<0.001)
DOI:
10.1038/tpj.2016.63
